The Flagship Pioneering spinout uses permanent bonds to target shallow pockets, drastically expanding the druggable universe for small molecules.

Industrial development of COFs is not as advanced, but companies involved with MOFs are keeping an eye on them. Ben Hernandez, the CEO of Numat Technologies, which has been developing MOFs for ...

Terremoto Biosciences is a company making waves in the drug development world. They’re using a pretty cool approach to create new medicines, focusing on how molecules interact at a chemical level.

Defining precisely where drugs engage their targets in vivo is essential for understanding efficacy and toxicity. However, mapping in vivo drug targets with spatial and cellular resolution remains ...

Biomea Fusion is a clinical-stage company focused on developing covalent small molecules for diabetes and genetically-defined cancers. The company highlighted positive phase 2 trial results for its ...

Graphene oxide is composed of oxygenated functional groups, the most prevalent of which are carboxyl, carbonyl, epoxy, and hydroxyl. These functional groups present on graphe are polar, making it very ...

Misbehaving proteins are behind many diseases. One way drugmakers incapacitate these bad actors is to deploy molecules that bind to them. But finding solid footholds on the proteins to block their ...

Attaching amino acids to a hydrophobic organic molecule allows them to self-assemble into rare, knotted structures with ...

In a recent study posted to the bioRxiv* preprint server, researchers performed an extensive library docking for new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) ...